DESFERAL

bottle deferoxamine mesilate: 500 mg Intramuscular route, intraperitoneal route, intravenous route (infusion), subcutaneous route (infusion) 20-40 mg/kg 1 time per day 20-60 mg/kg 1 time per day 15 mg/kg 1 time per hour 5 mg/kg 1 time per week 500 mg 1 time per day 5 mg/kg 1 time this day Renal failure The information provided on drug interactions results from the synthesis of the sources consulted by the Vidal scientific team.

They do not systematically reflect the information contained in the SPCs.

They are intended for practical purposes for health professionals.

The absence of an AMI in the Vidal database must never be interpreted as proof of safety. name: DESFERAL 500 mg Pdre/solv p sol inj Fl/500 mg+Amp/5 ml cip13:3400930298374 conservation: Cip: 3400930298374 Storage conditions: Before opening: < 25° for 36 months status: Marketed.

Primary hemochromatosis not curable by bloodletting.

Secondary hemosiderosis.

Acute martial poisoning.

Aluminum poisoning in renal failure patients on dialysis.

Diagnostic indications.

• Desferal test: screening for iron overload by measuring iron content

diagnosis of hemochromatosis, orientation of treatment and screening of latent forms in families of hemochromatosis subjects diagnosis of aluminum poisoning, particularly when the aluminum level is between and 3 micromoles/L (27-81 micrograms/L). lists: Primary hemochromatosis not curable by bloodletting.

• Desferal test: screening of iron overload by determination of iron content, diagnosis of hemochromatosis, orientation of treatment and screening of latent forms in families of hemochromatosis subjects, diagnosis of aluminum intoxication, in particular when the aluminemia is between and 3 micromoles/L (27-81 micrograms/L). screening for iron overload by measuring iron content, diagnosis of hemochromatosis, orientation of treatment and screening of latent forms in families of hemochromatosis subjects

diagnosis of aluminum poisoning, particularly when the aluminum level is between and 3 micromoles/L (27-81 micrograms/L). screening for iron overload by measuring iron content, diagnosis of hemochromatosis, orientation of treatment and screening of latent forms in families of hemochromatosis subjects diagnosis of aluminum poisoning, particularly when the aluminum level is between and 3 micromoles/L (27-81 micrograms/L).

Deferoxamine is a chelating agent for trivalent cations: ferric ion and trivalent aluminum ion; the complex formation constants are very high, respectively 10 and The affinity of deferoxamine for divalent ions such as Fe ++ , Cu ++ , Zn ++ , It ++ is significantly lower (complex formation constants ≤ 10 Chelation is carried out on a molar basis: 1 g of deferoxamine can theoretically complex 85 mg iron ferric (or 41 mg of Al +++ ).

Thanks to its properties, deferoxamine is able to fix the iron free from plasma or cells to form the ferrioxamine complex.

Urinary excretion of ferrioxamine is essentially a reflection of chelation of iron plasma, while fecal elimination mainly reflects chelation of iron intrahepatic. iron linked to ferritin or hemosiderin, but this is relatively unimportant at therapeutic concentrations of deferoxamine. iron of hemoglobin and cytochromes is inaccessible to deferoxamine.

Deferoxamine can also mobilize and chelate aluminum, thereby forming aluminoxamine.

Excretion of both ferrioxamine and aluminoxamine complexes is complete. iron and aluminum in urine and feces, thus reducing pathological deposits of iron or aluminum in the organs.